prilocaine
Genotype/Phenotype-based Prescribing Info
Prescribing information explains how to adjust treatment of certain medications based on a person’s genetic information, and includes information from clinical guideline annotations, drug label annotations and Rx study annotations.
Drug Label Annotations with Genotype-Based Prescribing Information
These are PharmGKB Drug Label Annotations with a "Prescribing" section. Information is added to this section if an annotation is tagged with "Dosing Info" or "Alternative Drug", or if any other guidance is given on the label for patients with a particular genotype or metabolizer phenotype. Examples of such guidance are (1) if a dosing change or alternate drug is "recommended", "suggested" or "should be considered", (2) if a drug "should be used with caution", or (3) if clinicians should "monitor" these patients for adverse events/reactions.
Annotation of FDA Label for lidocaine / prilocaine
Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.
Continue reading Annotation of FDA Label for lidocaine / prilocaine
Annotation of EMA Label for lidocaine / prilocaine
Although the systemic availability of prilocaine by cutaneous absorption of Fortacin is low, caution should be exercised in patients with anaemia, congenital or acquired methaemoglobinaemia or patients on concomitant therapy known to produce such conditions.
Continue reading Annotation of EMA Label for lidocaine / prilocaine
Annotation of HCSC Label for lidocaine / prilocaine
Patients with glucose-6-phosphate dehydrogenase deficiency or congenital or idiopathic methemoglobinemia are more susceptible to drug-induced methemoglobinemia. ORAQIX® (Lidocaine and Prilocaine Periodontal Gel) should not be used in those patients with congenital or idiopathic methemoglobinemia.
To minimize the risk of methemoglobinemai, BEFORE you use ORAQIX® talk to your dentist/dental hygienist if: [...]
- you have glucose 6-phosphate deficiencies.
Continue reading Annotation of HCSC Label for lidocaine / prilocaine